Kymera Therapeutics (KYMR) Share-based Compensation Growth (1y) (2020 - 2026)
Kymera Therapeutics (KYMR) Share-based Compensation Growth (1y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | -40.86% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 0.18% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 5,886.05% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Kymera Therapeutics | 10.77 Bn | 10.12 Bn | - | 12.46% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 12.46% |
| Dec 31, 2025 | -10.28% |
| Sep 30, 2025 | 393.16% |
| Jun 30, 2025 | 7.49% |
| Mar 31, 2025 | 18.93% |
| Dec 31, 2024 | -478.17% |
| Sep 30, 2024 | 27.88% |
| Jun 30, 2024 | 28.26% |
| Mar 31, 2024 | 27.52% |
| Sep 30, 2023 | 28.42% |
| Jun 30, 2023 | 16.20% |
| Mar 31, 2023 | 19.20% |
| Sep 30, 2022 | 22.71% |
| Jun 30, 2022 | 68.04% |
| Mar 31, 2022 | 148.20% |
| Dec 31, 2021 | -975.42% |
| Sep 30, 2021 | 217.70% |
| Jun 30, 2021 | 762.35% |
| Mar 31, 2021 | 754.99% |
| Dec 31, 2020 | 83.62% |